You are here

BCLDB Selects Seven Oaks Branded Cannabis Products for Sale in British Columbia

VANCOUVER, British Columbia, July 11, 2018 (GLOBE NEWSWIRE) -- Seven Oaks is excited to announce its brand will be available in British Columbia through Beleave Kannabis Corp. who has been selected by the BC Liquor Distribution Branch (BCLDB) to supply cannabis to BC retailers upon legalization.  

Seven Oaks’ founders are proud Metis from Winnipeg and aspire to make Seven Oaks Canada’s premier Indigenous brand focused on providing superior cannabis products for consumers. The name itself is a reference to a historical Metis battle site.

“We wanted to develop a brand that was a modern interpretation of the Metis spirit of freedom and adventure.  We’re proud to expand our distribution channels to the BC market and look forward to future announcements,” said Seven Oaks’ Co-Founder Grant McLeod.

Seven Oaks will initially have three hybrid strains containing limonene and pinene that were selected for their association with uplifting effects.  Products available in BC will include pouches of 1 g and 3.5 g of flower, while Seven Oaks anticipates having 1 g pre-rolled and half-gram pre-rolled packs coming in the future.

“Seven Oaks is for professionals like myself who use cannabis regularly while having active, productive lives,” said Grant.

Seven Oaks will continue to work closely with BCLDB, and all other stakeholders to ensure that we collectively deliver a cannabis system that provides professional and responsible access to high quality recreational cannabis.

Seven Oaks’ cannabis supply is coming from Beleave who has a well-established track record of growing superior cannabis without the use of pesticides providing a secure supply of high grade cannabis for the Seven Oaks brand. Beleave Inc. trades on the CSE as BE and the OTCQX as BLEVF.

Media Contact:

Grant McLeod, Co-Founder

Wednesday, July 11, 2018 - 17:07

More Headlines

Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
A meta-analysis that included 18 million participants found no protection from heart disease or stroke.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.
Some of that can be chalked up to the differences in cost of living from place to place, but not all.
Health plans expected to continue pushing for value-based payment arrangements.
One of the proposed changes makes remote patient monitoring an allowable cost.
European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.
Puts down $700 million to buy nearly 50% of Samsung.